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Fragment based drug discoveryFragment-based screening (FBS) has become an estab-
lished approach for hit identification. Starting points
identified by FBS, are small fragments that require
substantial modification to become leads. As fragments
are different from classical hits a process tailored for
fragment evolution is required. Scores for ligand effi-
ciency have been proposed as guides for this process.
Here we review how these have been applied to guide
the selection and optimization of fragment hits.
Introduction
A common approach for hit identification is high-throughput
screening (HTS) [1]. In HTS a large number of compounds
(106) are screened to assess biological activity against a target.
Nevertheless, considering the theoretically large chemical
space of drug-like compounds [2], the probability of finding
hits is relatively low [3]. This has led to the development of
alternative approaches such as FBS and fragment-based drug
discovery (FBDD) [4–15]. Advantages of FBS are (a) a more
efficient sampling due to the smaller chemical space of frag-
ment-sized compounds [16,17] and (b) a higher probability of
fragments possessing good complementarity with the target
[18]. Both aspects are likely to be the cause for the higher hit
rateswhichare typicallyobserved for FBS incomparison toHTS
[10]. However, fragment hits have lower affinities towards the
target. As a consequence, more effort has to be spent on*Corresponding author: Eric E.J. Haaksma (eric.haaksma@boehringer-ingelheim.com)
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optimization to obtain lead compounds with an acceptable
affinity. Strategies have been proposed to guide and evaluate
this process. These strategies aim at the efficient optimization
of fragments while maintaining their generally good physico-
chemical properties. In this review we discuss various effi-
ciency indices andhowtobest leverage theminFBDDprojects.
Considerations during hit selection and optimization
Traditionally, affinity is the first aspect considered for hit
selection and optimization. However, affinity alone can be
misleading as it is often found to be linkedwithmolecular size.
Thus a focus on affinity leads to a bias towards a selection of
biggercompounds. Inaddition,optimizationofaffinityduring
subsequent stages of drug discovery typically leads to a further
increase in molecular weight (MW) [19]. Moreover, affinity is
oftenoptimized throughthe introductionof lipophilic groups,
as these contribute favourably to the hydrophobic effect with-
out the need for specific interactions with the target. This
contrasts with polar groups, which need to establish very good
interactions with the target to compensate the desolvation
penalty. For this reason,polar groups are oftenused to improve
solubility rather than affinity [20]. This phenomenon is
reflected in the general trend towards generation of not only
bigger but also more lipophilic compounds during the hit
optimization process [19]..003 e157
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Table 1. Comparison of fragment-like and drug-like com-
pounds
Type of compound Fragment-like Drug-like
Rule Rule-of-Three* [34] Rule-of-Five [21]
Thresholds
MW <300 500
c log P 3 5
H-bond donors 3 5
H-bond acceptors 3 10
Typical values
pIC50 4.4
** 8
HA 15** 38
Ligand efficiencies
LE 0.38 0.29
FQ 0.55 0.81
* The authors suggest number of rotatable bonds 3 and polar surface area 60 as
additional useful criteria.
** Median values taken from the literature examples (see supplementary material).Ultimately, affinity for the target is not the only aspect that
has to be considered during drug discovery. To enter later
stages of drug development, a compound needs to have
suitable physicochemical properties. Lipinski et al. [21] stu-
died the properties of oral drugs that managed to enter
clinical Phase II. The study resulted in the ‘Rule-of-Five’
stating that poor absorption or permeation is more likely if
more than one of the relevant parameters (see Table 1) are
outside the range typically observed for drug-like com-
pounds.
The ‘Rule-of-Five’ has had a strong influence on the drug
discovery process. Good physicochemical properties help to
reduce the attrition rate at later stages towards tomarket [22].
A recent study showed that almost all ADMET parameters
deteriorate with either increasing MW and/or log P [23].
These studies emphasize the importance for selecting appro-
priate hits and monitoring MW and lipophilicity in addition
to affinity during hit optimization.
Ligand efficiency scores
Ligand efficiency
To escape the affinity-biased selection and optimization
towards larger ligands the focus should be directed towards
the generation of compounds that use their atoms most
efficiently. To estimate the efficiency of compounds, Hopkins
et al. [24] recommended to assess binding affinity in relation
to the number of heavy atoms in a molecule and introduced
the term ligand efficiency (LE)
LE ¼  DG
HA
whereDG is the free energy of binding andHA is the number
of non-hydrogen atoms of the ligand. Instead of considering
the affinity of the whole compound, the average affinity
contribution per atom is taken into account. This providese158 www.drugdiscoverytoday.coma way to compare the affinity of molecules corrected for their
size. Abad-Zapatero and Metz [25] introduced the binding
efficiency index (BEI) defined as BEI = pIC50/MW as an alter-
native metric. Prioritizing hits according to their LE allows
also smaller low affinity compounds to be attractive for
further optimization.
Group efficiency
Verdonk and Rees [26] introduced group efficiency (GE) as a
metric to compare the quality of added groups. It is defined as
GE ¼  DDG
DHA
DDG ¼ DGðBÞ  DDGðAÞ
DHA ¼ HAðBÞ HAðAÞ
where the affinity gained by molecule B, through the intro-
duction of additional non-hydrogen atoms DHA to molecule
A, is expressed as the difference of the free energies of binding
(DDG). The group efficiency describes the average affinity
gain contributed by each atom of an added group. Only the
addition of groups with the same (or a better) group effi-
ciency, compared to the LE of the initial molecule A, will
allow to maintain (or increase) the LE during compound
optimization.
Fit quality
Reynolds et al. systematically investigated the size-depen-
dence of LE [27]. In their study, the binding affinity data
and corresponding LEs taken from the BindingDB [28] were
plotted against the number on non-hydrogen atoms. Alto-
gether, over 8000 ligands for 28 targets were considered. The
result of their study is that the maximum observed ligand
efficiency decreases with molecular size. The authors con-
clude that LE cannot be evaluated independent of the mole-
cular size. To enable a size-independent comparison of
ligands they derived a scaling function (LE_Scale) by fitting
an exponential function to the maximal ligand efficiency
values observed for a given HA count. Dividing the actual
observed ligand efficiency by the calculated maximal achiev-
able ligand efficiency (the scaling function) results in a scaled
ligand efficiency called fit quality (FQ):
FQ ¼ LE
LE Scale
Different ways to obtain the scaling function are published
[29–31]. Nevertheless, independent of how the scaling func-
tion is derived, FQ values near one indicate near optimal
ligand binding.
Ligand-lipophilicity efficiency
LE and corresponding FQ are useful for optimizing affinity
with respect to molecular size. However, to achieve optimal
Vol. 7, No. 3 2010 Drug Discovery Today: Technologies | Fragment based drug discoveryADMET propertiesmolecular size and lipophilicity are impor-
tant factors to consider. If lipophilicity is too high, the like-
lihood of a compound to bind to multiple targets increases
[32]. To facilitate optimization of affinity with respect to
lipophilicity, Leeson and Springthorpe [32] defined the
ligand-lipophilicity efficiency (LLE):
LLE ¼ pIC50  clogP
High LLE favours compounds that gain a lot of their
affinity through directed interactions thus making the inter-
action with the receptor more specific.
While one can say that LLE describes how efficient a ligand
exploits its lipophilicity, no explicit measure of molecular
size is used. Therefore, a lipophilicity corrected LE is needed
to enable optimization of affinitywithout the extensive use of
lipophilic nonspecific interactions. Keseru and Makara [19]
proposed not only LELP = log P/LE as monitoring function to
achieve that goal, but also other ways to combine molecular
size and lipophilicity into a single efficiencymeasurement are
being discussed [33].
Application of ligand efficiency scores to FBDD
Clinical candidates are generally preferred to be ‘Rule-of-Five’
compliant with a special focus on lipophilicity. To achieve
this, the starting restrictions for fragments should be
obviously stronger. Congreve et al. [34] studied fragment hits
that could be successfully optimized into potent leads, and
noticed they have particular physicochemical properties.
These properties and congruent thresholds are summarized
as the ‘Rule-of-Three’ (see Table 1). To stay within these
thresholds has been suggested as a criterion for fragment
library design [34].
For fragment hit selection, LE has become a widely
accepted metric. In general, it is best to start with a fragment
that shows a high LE because in most cases LE decreases
during optimization. Looking at the examples in the litera-
ture [5–8,14] and following the evolution of LE, there are
fewer examples where LE could be maintained or even
increased. In the majority of examples (70%, see suppl.
material), LE decreases during fragment optimization (by
either fragment linking or growth). Therefore, starting with
a highly efficient fragment hit makes it easier to optimize the
fragment into a drug-like compound.
In general, an orally available clinical candidate possesses a
potency of better than 10 nM and, if ‘Rule-of-Five’-compli-
ant, a maximal molecular weight of 500 Da (which equals, on
average, 38 HA). This means that a LE of at least
0.29 kcal mol1 HA1 needs to be maintained during hit
optimization. Screening only ‘Rule-of-Three’-compliant frag-
ments ensures the identification of good starting points for
optimization if an affinity in the range of 1 mM can be
achieved. For a fragment hit with less than 300 Da (that
equals on average 23HA) this would result in a LE of at least0.36 kcal mol1 HA1. Looking at examples from the litera-
ture (see suppl. material) such a high affinity cannot always
be achieved (the median pIC50 is 4.35), but because the
average fragment hit is also smaller than 23 HA (median
number of HA is 15), the median LE of fragment hits con-
sidered here is 0.38 kcal mol1 HA1. Therefore, some loss of
LE during optimization is acceptable in most cases.
This is illustrated in the example (a) in Fig. 1: the LE score of
the initial fragment hit is quite high (0.59). Although, LE
decreases during fragment growth, the final potent com-
pound (IC50 = 3 nM) reaches a LE score of 0.42. This is still
a high value which is significantly above the suggested value
of about 0.3.
Another possible scenario is illustrated by example (b):
The LE score can be maintained throughout the optimiza-
tion process. This is achieved through the introduction of
groups that have GEs comparable to LE of the starting
compound. As long as the initial fragment hit has a LE
score > 0.3, also this strategy can lead to potent drug-like
compounds.
Example (c) shows one of the rare cases where LE is
increased during fragment growth. Although the LE of the
starting fragment is below 0.3, it was possible to significantly
improve the affinity by introducing an additional group to
finally reach a potent drug-like compound.
Revisiting example (a) illustrates the usefulness of FQ (in
addition to LE) for fragment optimization. Although LE is
decreasing, FQ is maintained, indicating that fragment
optimization is on the right track. In general, the goal
should be to either maintain or increase FQ during frag-
ment assembly to reach a near optimal affinity for the final
compound.
LLE provides a way to evaluate the affinity of a compound
with respect to its lipophilicity. The challenge is to increase
potency without increasing lipophilicity at the same time. As
lipophilicity is the major factor for promiscuity of com-
pounds, LLE optimized compounds should bemore selective.
It is suggested to target a LLE in a range of 5–7 or even higher
[32].
In example (a) LLE is increased during optimization. The
final compound reaches a LLE of 7.3 which is even above the
suggested range of 5–7. In combination with the acceptable
LE of 0.42 this indicates that this compound was successfully
optimized. Comparing the c log P values of the compounds
reveals that lipophilicity was kept fairly constant during
fragment growth. This means that affinity is mainly gained
by the introduction of groups making specific directed inter-
actions.
In the other two examples, (b) and (c) LLE is increasing
during optimization but none of the compounds reaches a
LLE above 5. In these cases the gain of affinity is accompanied
by an increase of lipophilicity. In this respect, optimization
was not as optimal as in the first example.www.drugdiscoverytoday.com e159
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Figure 1. Examples of successful fragment-based drug discovery campaigns (a) Aurora [38], (b) PDE4B [39], and (c) p38a [40,41].Conclusions
FBDD, as illustrated in Table 1, typically starts with a ‘Rule-of-
Three’-compliant fragment and ideally ends up with a potent
‘Rule-of-Five’-compliant candidate compound. Colleagues
from Astex proposed that an efficient fragment growth is
one where LE can be maintained [4]. This goal is further
supported by a study which concluded that a linear increase
of binding affinity with molecular mass is possible [35]. If
maintenance of LE at an acceptable level (LE  0.3) can be
achieved, FQ scores will rise during fragment growth and the
affinity of the final compound will approach a near optimal
affinity.e160 www.drugdiscoverytoday.comAt the same time, retrospective studies show that in most
cases LE scores decrease during fragment assembly [5,8]. Still,
an acceptable affinity of the final compound can be reached if
FQ can be maintained at a high level (FQ  0.8). Therefore,
Bembenek et al. [36] suggested that, unlike LE alone, the FQ
score can be used as a measure of efficiency across the entire
optimization process from initial fragment hit to optimized
clinical candidate.
Another mentionable guide to maintain the good physi-
cochemical properties of fragment hits is to consider LLE
during FBDD. Lipinski states in the ‘Rule-of-Five’ that the
c log P, which is used to calculate the LLE, should be smaller
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Table 2. Summary of ligand efficiency scores to be considered during FBDD
Parameter Definition Focus during fragment
hit selection leads to
Recommended range
for fragment hits
Aim during fragment
optimization
Ligand efficiency LE = DDG/HA Bias towards smaller
compounds
LE  0.3 Try to maintain (decrease acceptable for
starting fragments with LE  0.3)
Fit quality FQ = LE/LE_Scale Size independent selection
of efficient compounds
FQ  0.8 Maintain at high level or increase to FQ  1
Ligand-lipophilicity
efficiency
LLE = pIC50  log P Selection of more
specific compounds
LLE  3 Maintain at high level or increase to LLE > 5–7than 5. However, a 10 nM compound with an acceptable
c log P of 5 will have a LLE of 3. This is much smaller than the
suggested range of 5–7 [32]. To achieve a LLE in this range, the
c log P must be smaller than 3. This is in agreement with a
recent study which showed that there is an increased risk of
adverse outcome with c log P > 3 [37].
Table 2 summarizes the ligand efficiency scores that should
be considered during FBDD. Both LE and FQ have been very
helpful in guiding the selection and optimization of fragment
hits. In addition, LLE is expected to become increasingly
popular to ensure an increase of affinity more than lipophi-
licity.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.ddtec.2010.11.003.
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